Coastal barium cycling at the West Antarctic Peninsula

Barium cycling in the ocean is associated with a number of processes, including the production and recycling of organic matter, freshwater fluxes, and phenomena that affect alkalinity. As a result, the biogeochemical cycle of barium offers insights into past and present oceanic conditions, with barium currently used in various forms as a palaeoproxy for components of organic and inorganic carbon storage, and as a quasi-conservative water mass tracer. However, the nature of the oceanic barium cycle is not fully understood, particularly in cases where multiple processes may be interacting simultaneously with the dissolved and particulate barium pools. This is particularly the case in coastal polar regions such as the West Antarctic Peninsula, where biological drawdown and remineralisation occur in tandem with sea ice formation and melting, glacial meltwater input, and potential fluxes from shelf sediments. Here, we use a high-precision dataset of dissolved barium (Bad) from a grid of stations adjacent to the West Antarctic Peninsula in conjunction with silicic acid (Si(OH)4), the oxygen isotope composition of water, and salinity measurements, to determine the relative control of various coastal processes on the barium cycle throughout the water column. There is a strong correlation between Bad and Si(OH)4 present in deeper samples, but nevertheless persists significantly in surface waters. This indicates that the link between biogenic opal and barium is not solely due to barite precipitation and dissolution at depth, but is supplemented by an association between Bad and diatom tests in surface waters, possibly due to barite formation within diatom-dominated phytodetritus present in the photic zone. Sea-ice meltwater appears to exert a significant secondary control on barium concentrations, likely due to non-conservative biotic or abiotic processes acting as a sink for Bad within the sea ice itself, or sea-ice meltwater stimulating non-siliceous productivity that acts as a Bad sink. Meteoric water input, conversely, exerts little or no control on local barium levels, indicating that glacial meltwater is not a significant coastal source of barium to the West Antarctic Peninsula shelf waters

PAM50 molecular intrinsic subtypes in the nurses' health Study cohorts

Background: Modified median and subgroup-specific gene subtypes by PAM50 and IHC surrogates improved to fair centering are two essential preprocessing methods to assign when Luminal subtypes were grouped together. Using the breast cancer molecular subtypes by PAM50. We evaluated the modified median method, our study consisted of 46% PAM50 subtypes derived from both methods in a subset of Luminal A, 18% Luminal B, 14% HER2-enriched, 15% Nurses' Health Study (NHS) and NHSII participants; correlat-Basal-like, and 8% Normal-like subtypes; 53% of tumor-ed tumor subtypes by PAM50 with IHC surrogates; and adjacent tissues were Normal-like. Women with the Basal-characterized the PAM50 subtype distribution, proliferation like subtype had a higher rate of relapse within 5 years. scores, and risk of relapse with proliferation and tumor size HER2-enriched subtypes had poorer outcomes prior to weighted (ROR-PT) scores in the NHS/NHSII. 1999. Methods: PAM50 subtypes, proliferation scores, and Conclusions: Either preprocessing method may be uti-ROR-PT scores were calculated for 882 invasive breast tumors lized to derive PAM50 subtypes for future studies. The and 695 histologically normal tumor-adjacent tissues. Cox majority of NHS/NHSII tumor and tumor-adjacent tissues proportional hazards models evaluated the relationship were classified as Luminal A and Normal-like, respectively. between PAM50 subtypes or ROR-PT scores/groups with Impact: Preprocessing methods are important for the recurrence-free survival (RFS) or distant RFS. accurate assignment of PAM50 subtypes. These data provide Results: PAM50 subtypes were highly comparable evidence that either preprocessing method can be used in between the two methods. The agreement between tumor epidemiologic studies

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer : results from the Breast International Group Trial 1-98

The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60-80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is associated with improved survival for this subtype in epidemiologic studies. However, whether AR expression modifies the efficacy of selective ER modulators or aromatase inhibitors for ER+ cancers remains unclear